Contact SCGE




Clinical Trial Report

Gene Therapy Trial Report

Summary

SCID-X1 Gene Therapy Via Intravenous Lentiviral (Ivlv-X1) Injection


NCTID NCT03217617 (View at clinicaltrials.gov)
Description
Development Status Active
Indication X-linked Severe Combined Immunodeficiency (XSCID)
Disease Ontology Term DOID:0060013
Compound Name Ivlv-X1 lentiviral vector
Sponsor Shenzhen Geno-Immune Medical Institute
Funder Type Other
Recruitment Status
Recruiting
Enrollment Count 10
Results Posted Not Available

Therapy Information


Target Gene/Variant IL2RG
Therapy Type Gene transfer
Therapy Route In-vivo
Mechanism of Action Functional gene replacement
Route of Administration Intravenous
Drug Product Type Viral vector
Target Tissue/Cell
Delivery System Viral transduction
Vector Type LV
Editor Type
Dose 1 1E9 vg/kg
Dose 2
Dose 3
Dose 4
Dose 5

Study Record Dates


Current Stage Phase1, Phase2
Submit Date 2017-07-03
Completion Date 2027-12-31
Last Update 2024-07-08

Participation Criteria


Eligible Age 1 Month - 1 Year
Standard Ages Child
Sexes Eligible for Study MALE

Locations


No.of Trial Sites 2
Locations China

Regulatory Information


Has US IND False
FDA Designations
Recent Updates

Resources/Links


Resources/Links

No External Links Available.